Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010‒2017)
Given the low mortality, high proportions of polysubstance mortality, and the mixed agonist/antagonist mechanism of action, use of buprenorphine alone likely presents a lower risk for overdose than comparators. Mortality rose faster than dispensing, signaling need to ensure people understand buprenorphine risks, particularly polysubstance use, balanced against importance for treating opioid use disorders.
Authors
- Joshua Curtis Black (ORCID: https://orcid.org/0000-0002-7329-2740)
- Gabrielle E. Bau (ORCID: https://orcid.org/0000-0003-3680-7837)
- Karilynn M. Rockhill (ORCID: https://orcid.org/0000-0003-2831-4055)
- Janetta Iwanicki
- Howard D. Chilcoat (ORCID: https://orcid.org/0000-0001-6715-0044)
- Richard C. Dart (ORCID: https://orcid.org/0000-0001-5989-9354)
- Angela DeVeaugh‐Geiss
Institutions
- Hospital Authority (HK)
- Johns Hopkins University (US)
- Denver Health Medical Center (US)
- Indivior (United States) (US)
- Health and Hospital Corporation (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of the American College of Emergency Physicians Open
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/emp2.13338
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Indivior